R&D-based pharma firms and European parallel traders are contributing to the emergency relief effort in Ukraine and to the refugee crisis by making financial donations to humanitarian organizations or sending medicines and other medical supplies directly to Ukraine.

The European Medicines Agency is expected to make recommendations on EU marketing authorization for 10 new medicines at its monthly meeting this week. They include products for non-small cell lung cancer, COVID-19, kidney disease, smallpox and migraine.